NuCana (NASDAQ:NCNA) Trading Up 2.9% – Still a Buy?

NuCana PLC Sponsored ADR (NASDAQ:NCNA – Get Free Report)’s share price shot up 2.9% during mid-day trading on Thursday . The company traded as high as $1.44 and last traded at $1.43. 49,000 shares changed hands during trading, a decline of 50% from the average daily volume of 97,747 shares. The stock had previously closed at $1.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Get NuCana alerts:

Check Out Our Latest Report on NuCana

NuCana Price Performance

The firm has a market cap of $5.95 million, a PE ratio of -0.38 and a beta of 2.23. The firm has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $1.77.

NuCana (NASDAQ:NCNA – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.65) by $1.66.

NuCana Company Profile

(Get Free Report)

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.

See Also

• Five stocks we like better than NuCana
• The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
• NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
• Dropping the Dough: Yum! Brands Strategically Trims the Fat
• These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.